The Snowflake security team knew traditional data protection tools, like DLP and CASB, were too cumbersome and not effective at providing them the visibility they needed. Learn how they built an Insider Risk Management program that gave them visibility…
Slow contract negotiations are why legal departments are often seen as business bottlenecks. But what if you could compress contract negotiation cycle times and operate at the speed of business? We conducted a series of time and motion studies with lar…
Instead of investigating employees the same way we investigate external threats, we must take a more empathetic approach. The majority of untrusted data movement is non-malicious. Whatever the intention – whether source code is taken to a competitor…
Today’s attackers assign a level of value to workforce passwords they once reserved for privileged users’ credentials. Why? Employees now have a shocking amount of access to sensitive resources – often through the applications they us…
Serious Injuries and Fatalities (SIFs) are complex and difficult to predict, but companies who understand the context of these types of injuries can better identify leading indicators that may prevent a SIF from occurring. Even though the total number …
For Principal Investigators- a notice for an inspection can create anxiety. Identifying expectations and establishing a plan, however, can significantly mitigate stress even for decentralized trials. What do you need to be Inspection Ready for your pro…
Switching providers can be time-consuming and overwhelming, especially if you’ve made a recent change that’s not working out. Making a smooth decision requires understanding your organization’s specific needs and finding the right pro…
Most leaders agree that employee recognition is a good thing. But too many organizations struggle to do employee recognition in a way that actually impacts the employee experience and the business bottom line. That’s why we built this workbook&md…
With current market volatility and operational challenges making daily headlines, biotech organizations are always confronting new challenges in developing cell and gene therapies. How does your organization navigate evolving regulatory guidel…
In order to accelerate time to market, some pharma companies default to the fastest available primary container for their drug product. However, the interaction between the container and drug product is often underestimated and under-characterized, whi…
